alpha-aminopyridine has been researched along with Anemia, Sickle Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, EA; Afangbedji, N; Almeida, LEF; Ivanov, A; Jerebtsova, M; Khaibullina, A; Kumari, N; Nekhai, S; Quezado, ZMN | 1 |
| Abbadessa, G; Andrews, RK; Barazia, A; Cho, J; Gordeuk, VR; Kim, K; Li, J; Schwartz, B; Tseng, A; Youn, SW; Yu, Y | 1 |
2 other study(ies) available for alpha-aminopyridine and Anemia, Sickle Cell
| Article | Year |
|---|---|
RON kinase inhibition reduces renal endothelial injury in sickle cell disease mice.
Topics: Aminopyridines; Anemia, Sickle Cell; Animals; Cells, Cultured; Endothelium, Vascular; Humans; Kidney; Macrophages; Mice; Pyridones; Receptor Protein-Tyrosine Kinases | 2018 |
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Topics: Administration, Oral; Adult; Aminopyridines; Anemia, Sickle Cell; Animals; Biomarkers; Blood Platelets; Cell Adhesion; Cell Communication; Disease Models, Animal; Female; Humans; Hydroxyurea; Imidazoles; Male; Mice, Knockout; Middle Aged; Neutrophil Activation; Neutrophils; Nitric Oxide; Oxidation-Reduction; Phosphorylation; Platelet Activation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transendothelial and Transepithelial Migration; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2017 |